risedronic acid has been researched along with Jaw Diseases in 14 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Jaw Diseases: Diseases involving the JAW.
| Excerpt | Relevance | Reference |
|---|---|---|
| "etidronate) have been associated with acute renal failure." | 2.44 | Safety considerations with bisphosphonates for the treatment of osteoporosis. ( Civitelli, R; Emkey, R; Strampel, W, 2007) |
| "Alendronate was the most frequently implicated (six cases) and risedronate (five cases)." | 1.36 | [Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. ( Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B, 2010) |
| "No osteonecrosis was noted immediately postoperatively or during the follow-up period in 61 patients." | 1.34 | Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices. ( Fugazzotto, PA; Jaffin, R; Kumar, A; Lightfoot, WS, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (71.43) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geusens, P | 1 |
| Kunchur, R | 1 |
| Need, A | 1 |
| Hughes, T | 1 |
| Goss, A | 1 |
| Lo, JC | 1 |
| O'Ryan, FS | 1 |
| Gordon, NP | 1 |
| Yang, J | 1 |
| Hui, RL | 1 |
| Martin, D | 1 |
| Hutchinson, M | 1 |
| Lathon, PV | 1 |
| Sanchez, G | 1 |
| Silver, P | 1 |
| Chandra, M | 1 |
| McCloskey, CA | 1 |
| Staffa, JA | 1 |
| Willy, M | 1 |
| Selby, JV | 1 |
| Go, AS | 1 |
| Kwon, YD | 1 |
| Kim, DY | 1 |
| Ohe, JY | 1 |
| Yoo, JY | 1 |
| Walter, C | 1 |
| Migliorati, CA | 1 |
| Mattos, K | 1 |
| Palazzolo, MJ | 1 |
| Barrier, A | 1 |
| Lescaille, G | 1 |
| Rigolet, A | 1 |
| Descroix, V | 1 |
| Goudot, P | 1 |
| Ruhin, B | 1 |
| Pazianas, M | 1 |
| Scully, C | 1 |
| Brooks, JK | 1 |
| Gilson, AJ | 1 |
| Sindler, AJ | 1 |
| Ashman, SG | 1 |
| Schwartz, KG | 1 |
| Nikitakis, NG | 1 |
| Malden, NJ | 1 |
| Pai, AY | 1 |
| Strampel, W | 1 |
| Emkey, R | 1 |
| Civitelli, R | 1 |
| Fugazzotto, PA | 1 |
| Lightfoot, WS | 1 |
| Jaffin, R | 1 |
| Kumar, A | 1 |
| Marx, RE | 1 |
| Cillo, JE | 1 |
| Ulloa, JJ | 1 |
| Khan, A | 1 |
3 reviews available for risedronic acid and Jaw Diseases
| Article | Year |
|---|---|
Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Frac | 2009 |
Osteonecrosis of the jaw and the role of macrophages.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone | 2011 |
Safety considerations with bisphosphonates for the treatment of osteoporosis.
Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphospho | 2007 |
1 trial available for risedronic acid and Jaw Diseases
| Article | Year |
|---|---|
Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Co | 2009 |
10 other studies available for risedronic acid and Jaw Diseases
| Article | Year |
|---|---|
Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; California; Cross-Section | 2010 |
Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Conservation Ag | 2009 |
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conser | 2010 |
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmu | 2010 |
Potential adverse effects.
Topics: Bone Density Conservation Agents; Etidronic Acid; Humans; Jaw Diseases; Osteonecrosis; Periodontal D | 2006 |
Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Dental Implantation, Endosseous; Etidr | 2007 |
Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Bo | 2007 |
Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Dental | 2007 |
Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Etidroni | 2007 |
Osteonecrosis of the jaw: new developments in an old disease.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Eti | 2008 |